Attorney Docket: 03-0078 (US01)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

David K. Swanson

Serial No.: 10/727,149

Filed: December 2, 2003

For: SURGICAL METHODS AND APPARATUS FOR MAINTAINING CONTACT BETWEEN TISSUE AND ELECTROPHYSIOLOGY ELEMENTS AND CONFIRMING WHETHER A THERAPEUTIC LESION HAS BEEN FORMED

Group Art Unit: 3739

Confirmation No.: 5299

Examiner: Vrettakos, Peter J.

.

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 CFR § 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. Copies of US Patents and US Patent Publications are not enclosed, pursuant to the US Patent & Trademark Office amendment to the 37 CFR § 1.98(a)(2)(i) that eliminates the requirement for a copy of each U.S. patent or U.S. patent application publication listed in an IDS in a patent application regardless of the filing date of the application. Copies of other cited references are enclosed.

Applicant would like to bring to the attention of the Examiner that U.S. Patent Application Serial Nos. 10/727,096 (US Pub. 2005-0119648), 10/784,316 (US Pub. 2005-0187544), 10/395,021 (US Pub. 2004-0186467) 11/141,405 (US Pub. US 2006-0271034 and 10/727,143 (US Pub. 2005-0119653), PCT/US2004/039283, PCT/US2004/039143, PCT/US2004/039282, PCT/US2004/05883, and European Patent Application No.

Attorney Docket: 03-0078 (US01)

04715649.2 (EP Patent No. 1605841) claim subject matter that may be similar to the subject matter claimed in the present application.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

## INFORMATION DISCLOSURE STATEMENT FILING PROVISION:

1.97(b continution of the Office	), that ued pro nationa action	OS is believed to be timely in that it is being submitted under 37 CFR § is (1) within three months of the filing date of the application, which is not a essecution application filed under § 1.53(d) or (2) within three months of entry all stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a first on the merits; or (4) before the mailing of a first Office action after filing a continued examination under § 1.114. Thus, no fee is required.	
		However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR §1.17(p) to the deposit account referenced below.	
		However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR $\S$ 1.97(c), if applicable, and a statement under 37 CFR $\S$ 1.97(e) is included below, thus no fee is required.	
Office	action	OS is being submitted under 37 CFR § 1.97(c), that is after mailing of a first on the merits, but before a Final Action under 37 CFR § 1.113 or a Notice of oder 37 CFR § 1.311.  The fee due under 37 CFR § 1.17(p) is submitted herewith.	
		A statement under 37 CFR § 1.97(e) is included below, thus no fee is required. In the event that this IDS is not received before a Final Action or a Notice of Allowance, then Applicant respectfully requests that the Office consider the filing of these papers to be submitted under 37 CFR § 1.97(d) and charge the fee due under 37 CFR § 1.17(p) to the deposit account below.	
□ under	This IDS is being submitted under 37 CFR § 1.97(d), that is after a Final Action 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311, but before		

Attorney Docket: 03-0078 (US01)

payment of the issue fee. A statement under 37 CFR § 1.97(e) is included below. The fee due under 37 CFR § 1.17(p) is submitted herewith.

	;	STATEMENT UNDER 37 CFR § 1.97(e):		
	Each item contained	d in this IDS was first cited in any communication from a foreign		
patent	t office in a counterpa	art foreign application not more than three months prior to the		
filing c	of this IDS.			
	No item contained in	this IDS was cited in a communication from a foreign patent		
office	in a counterpart forei	gn application, and, to the knowledge of the person signing		
this st	atement after making	reasonable inquiry, no item of information contained in this		
IDS w	as known to any indi	vidual designated in 37 CFR § 1.56(c) more than three months		
prior to	o the filing of this IDS	<b>).</b>		
	Рауме	NT AND/OR AUTHORIZATION TO CHARGE FEES:		
	A check in the amount of is enclosed for the above fee(s).  Fee(s) due under 37 CFR § 1.17(p) in the amount of \$180.00 is paid via EFS Web. Although applicant believes no fee is required, the Commissioner is authorized to charge any fees required by the filing of these papers, and to credit any overpayment to Vista IP Law Group LLP Deposit Account No. 50-1105.			
		Respectfully submitted, VISTA IP LAW GROUP LLP		
Dated	: October 23, 2007	By: /Gary D. Lueck/ Gary D. Lueck Reg. No. 50,791		
	Customer Number <b>41696</b> PATENT TRADEMARK OFFICE	VISTA IP LAW GROUP LLP 12930 Saratoga Avenue, Suite D-2 Saratoga, CA 95070 Phone (408) 777-2905 Fax (408) 877-1662		